Results 71 to 80 of about 75,992 (272)

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [PDF]

, 2016
BACKGROUND: Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus ipilimumab in patients with SCLC who progressed after one or more prior ...
Taylor, Matthew, C. T. Harbison, Harbison, Christopher T., M. A. Morse, Amin, Asim, de Braud, Filippo, M. . C. Pietanza, D. T. Le, E. Calvo, L. Horn, Calvo, Emiliano, P. Bono, A. Atmaca, J. A. López Martin, Chau, Ian, Christensen, Olaf, O. Christensen, Jäger, Dirk, J. Bendell, J. P. Eder, Ascierto, Paolo A., I. Chau, Pillai, Rathi N., Bono, Petri, Lin, Chen-Sheng, P. Sharma, Bendell, Johanna, P. A. Ott, Horn, Leora, Atmaca, Akin, F. de Braud, Sharma, Padmanee, Jaeger, Dirk, Evans, Jeffry, López-Martin, José A., Antonia, Scott J., Eder, Joseph Paul, Pietanza, M. Catherine, S. J. Antonia, J. Evans, Le, Dung T., C. Lin, P. A. Ascierto, A. Amin, D. Jäger, Morse, Michael A., Ott, Patrick A., M. Taylor, R. N. Pillai   +48 more
core   +1 more source

Prevalence of MSI‐H/dMMR Colorectal Cancer in Japan: Data From the Clinical Study Group of the University of Osaka‐Colorectal Registry

Annals of Gastroenterological Surgery, EarlyView.
Using a multicenter Japanese colorectal cancer cohort from 25 institutions, we analyzed 1464 patients across all disease stages and tumor locations to determine the prevalence and clinicopathological features of MSI‐H/dMMR colorectal cancer. MSI‐H/dMMR tumors accounted for 9.4% of cases overall, were present in 22% of right‐sided colon cancers, and ...
Yoshihiro Morimoto, Mamoru Uemura, Yoshinori Kagawa, Hidekazu Takahashi, Masayuki Hiraki, Yozo Suzuki, Shinichi Yoshioka, Mitsuyoshi Tei, Shu Okamura, Yukako Mokutani, Atsushi Naito, Shinji Tokuyama, Takamichi Komori, Akinobu Yasuyama, Genta Sawada, Yujiro Fujie, Shinya Yamashita, Naotsugu Haraguchi, Yusuke Matsuura, Chu Matsuda, Yoshinao Chinen, Tatsushi Shingai, Katsuki Danno, Nobuo Tanaka, Kazuya Sakata, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi   +27 more
wiley   +1 more source

Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma

Ear, Nose & Throat Journal, 2021
Objectives: Present the case of a 67-year-old male with stage IV malignant melanoma who presented with uveitis and sensorineural hearing loss (SNHL) while on nivolumab and review the literature for likely etiologies.
Alex J. F. Tampio MD, Swetha Dhanireddy MD, Abirami Sivapiragasam MD, Brian D. Nicholas MD   +3 more
doaj   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia

, 2016
Purpose: The aim of this study was to evaluate the cost-effectiveness of nivolumab versus ipilimumab for the treatment of previously untreated patients with BRAF-advanced melanoma (BRAF-AM) from an Australian health system perspective.
Liew, Danny, Gorelik, Alexandra, Kim, Hansoo, Bohensky, Megan A, Harrison, James P, Pasupathi, Kumar   +5 more
core   +1 more source

Myofasciitis under nivolumab treatment

, 2021
We report the case of a 73-year-old female patient with malignant melanoma who developed rapidly progressive dermatosclerosis of the arms and legs as well as myalgia and flexion contractures during treatment with the immune checkpoint inhibitor nivolumab.
Keller, Sarah, Krusche, Martin, Geisler, Carolin, Stenzel, Werner, Ohrndorf, Sarah, Schneider, Udo   +5 more
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma

Urology Case Reports, 2020
In the Checkmate-025 trial, nivolumab treatment prolonged overall survival among patients with previously treated advanced renal cell carcinoma (RCC) compared with treatment with everolimus. Although effective, nivolumab is associated with immune-related
Shinro Hata, Satoki Abe
doaj   +1 more source

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. [PDF]

PLoS ONE, 2018
BACKGROUND:The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation.
Monica Khunger, Pradnya Dinkar Patil, Arjun Khunger, Manshi Li, Bo Hu, Sagar Rakshit, Arnab Basu, Nathan Pennell, James P Stevenson, Paul Elson, Tanmay S Panchabhai, Vamsidhar Velcheti   +11 more
doaj   +1 more source